Microneedle device and application method thereof

A microneedle device with specified dimensions and application load enhances skin barrier function by increasing mRNA expression and ceramide levels in a three-dimensional cultured skin model without penetrating the stratum corneum, addressing the issue of conventional damage.

JP2024158332APending Publication Date: 2024-11-08HISAMITSU PHARM CO INC
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2023073455
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-04-27
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Conventional microneedle devices penetrate the stratum corneum, causing damage to the epidermis and superficial dermis, necessitating a method that enhances skin barrier function without penetration.

Method used

A microneedle device with microneedles of specific length (300 μm to 900 μm) and density (28 to 640 pieces/cm²) applied with a load of 0.5N to 1.5N to a three-dimensional cultured skin model, enhancing mRNA expression of genes like SPTLC3, FLG, and TGM1, and increasing ceramide levels without penetrating the stratum corneum.

Benefits of technology

The device effectively enhances skin barrier function by increasing mRNA expression and ceramide levels in the skin without causing damage, indicating potential wrinkle improvement.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024158332000001
    Figure 2024158332000001
  • Figure 2024158332000002
    Figure 2024158332000002
  • Figure 2024158332000003
    Figure 2024158332000003
Patent Text Reader

Abstract

To provide an application method of a microneedle device in which a microneedle does not completely penetrate a keratinous layer of a skin, increases an expression level of mRNA of a gene related to enhancement of a skin barrier function, and can increase a ceramide amount.SOLUTION: A method of increasing an mRNA expression level of a gene related to enhancement of a skin barrier function in a three-dimensional cultured skin and a ceramide amount includes application of a microneedle device equipped with a base plate and a microneedle arranged on the base plate on the three-dimensional cultured skin. A length of the microneedle is 300 to 900 μm, and the microneedle is arranged on the base plate at density of 28 needles / cm2 to 640 needles / cm2. A load of applying the microneedle device on the three-dimensional cultured skin is 0.5 to 1.5 N.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a microneedle device and an application method thereof, and more particularly to a microneedle device for increasing the mRNA expression level of a gene associated with enhancement of skin barrier function and the amount of ceramide in three-dimensionally cultured skin, and a method for increasing the mRNA expression level of a gene associated with enhancement of skin barrier function and the amount of ceramide in three-dimensionally cultured skin. [Background technology]

[0002] Conventionally, a device having microprotrusions on a substrate (microprotrusion array) has been known as a device for improving the transdermal absorption of drugs. The purpose of the microprotrusions is to puncture the stratum corneum, which is the outermost layer of the skin, and various sizes and shapes have been proposed (see Patent Document 1).

[0003] Various methods have also been proposed for applying drugs when using an array with microprotrusions. Patent Document 2 describes coating the surface of the microprotrusions with a drug, providing grooves or hollow parts in the microprotrusions to allow the drug or biological components to pass through, mixing the drug into the microprotrusions themselves, etc. Patent Document 2 also describes that the reservoir medium preferably contains sugars, and in particular contains stabilizing sugars such as lactose, raffinose, trehalose, or sucrose that form glass (amorphous solid material).

[0004] Patent Documents 3 and 4 describe that by making the height of the microprotrusions 10 μm to 3 mm and making the tip shape of the microprotrusions flat or rounded, the microprotrusions can stretch the epidermis without penetrating the stratum corneum, and can administer compounds such as cosmetics, medicines, plastics, etc. attached to or contained in the protrusions.

[0005] Patent Document 5 describes a device comprising a substrate, an array with microprotrusions having tapered microprotrusions that are provided on the substrate and connect to the substrate and become thinner from the bottom to the tip, and a pressing means for applying the array with microprotrusions to the skin, in which, when the distance from the tip to the bottom on any side of the microprotrusions is a and the length of a second line segment formed by projecting a first line segment indicating said distance onto the substrate is b, the relationship is 1.0<(a / b)≦7.5, the height of the microprotrusions is 50 to 300 μm, and the microprotrusions do not penetrate the stratum corneum of the skin.

[0006] Patent Document 6 describes a method of using a protruding device that can suppress damage to the stratum corneum and achieve a blood flow promotion effect simply by pressing the protruding device against the skin, in which a protruding device containing a thermoplastic resin and having fine protrusions with a tip diameter of 10 μm to 400 μm is pressed against the skin in a non-invasive or minimally invasive manner.

[0007] Non-Patent Document 1 states that the microneedle method is effective by damaging the epidermis and superficial dermis, and aims to induce the expression of collagen and elastin as well as improve skin structure.

[0008] Non-Patent Document 2 describes that combined treatment with wrinkle cream and microneedle patch significantly improved IGA scores for crow's feet and nasolabial folds compared to the application of wrinkle cream or patch alone. [Prior art documents] [Patent documents]

[0009] [Patent Document 1] Special Publication No. 2001-506904 [Patent Document 2] Special Publication No. 2004-504120 [Patent Document 3] JP 2007-089792 A [Patent Document 4] JP 2007-130417 A [Patent Document 5] International Publication No. 2011 / 148994 [Patent Document 6] JP 2022-188715 A [Non-patent literature]

[0010] [Non-Patent Document 1] Robati et al., "Efficacy of microneedling versus fractionalEr:YAG laser in facial rejuvenation", J Cosmet Dermatol, 2020, 19(6):1333-1340. [Non-Patent Document 2] Hong et al., "Efficacy and safety of a novel, solublemicroneedle patch for the improvement of facial wrinkles", J CosmetDermatol, 2018, 17(2): 235-241. Summary of the Invention [Problem to be solved by the invention]

[0011] Conventionally, when applying a microneedle device to the skin to enhance the skin barrier function, it was necessary to damage the epidermis and superficial dermis, i.e., for the microneedles to penetrate the stratum corneum of the skin. [Means for solving the problem]

[0012] In order to avoid the possibility of damaging the skin, a microneedle device is desirable in which the microneedles do not completely penetrate the stratum corneum of the skin (do not damage the epidermis and superficial dermis) and can induce factors related to the enhancement of the skin barrier function under such application conditions. As a result of detailed studies by the present inventors, in a test using a three-dimensional cultured skin model, it was found that when a microneedle device in which microneedles of a predetermined length are arranged on a substrate at a predetermined density is applied to the skin under a predetermined load, the expression level of mRNA of a gene related to the enhancement of the skin barrier function and the amount of ceramide are increased, even though the microneedles do not penetrate the stratum corneum of the skin, and the present invention was completed. That is, the present invention includes the following [1] to [4]. [1] A method for increasing the mRNA expression level and ceramide level of a gene associated with enhancement of skin barrier function in three-dimensionally cultured skin, comprising: applying to the three-dimensional cultured skin a microneedle device comprising a substrate and a microneedle disposed on the substrate; The length of the microneedle is 300 μm to 900 μm, The above microneedles are 28 pieces / cm 2 ~640 pieces / cm 2 are disposed on the substrate at a density of The load when applying the microneedle device to the three-dimensional cultured skin is 0.5N to 1.5N. method. [2] The method according to [1], wherein the gene associated with enhanced skin barrier function is one or more genes selected from the group consisting of SPTLC3, FLG and TGM1. [3] A microneedle device for increasing the mRNA expression level and ceramide level of a gene related to enhancement of skin barrier function in three-dimensionally cultured skin, A substrate and a microneedle disposed on the substrate, The length of the microneedle is 300 μm to 900 μm, The above microneedles are 28 pieces / cm 2 ~640 pieces / cm 2are disposed on the substrate at a density of The load applied to the microneedle device when applied to the three-dimensional cultured skin is 0.5N to 1.5N. Microneedle device. [4] The microneedle device described in [3], wherein the gene associated with enhanced skin barrier function is one or more genes selected from the group consisting of SPTLC3, FLG and TGM1. Effect of the Invention

[0013] According to the present invention, it is possible to provide a microneedle device and an application method thereof, in which the microneedles do not completely penetrate the stratum corneum of the skin, the expression level of mRNA of a gene involved in enhancing the skin barrier function, and the amount of ceramide can be increased. When such a microneedle device is applied, effects such as wrinkle improvement can be expected. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] The present invention will be described in detail below by showing embodiments of the present invention.

[0015] The microneedle device according to one embodiment of the present invention is for increasing the amount of ceramide and the amount of mRNA expression of a gene associated with enhancement of skin barrier function in three-dimensionally cultured skin, and comprises a substrate and microneedles arranged on the substrate, the length of the microneedles being 300 μm to 900 μm, and the microneedles being arranged at a density of 28 per cm. 2 ~640 pieces / cm 2 The microneedle devices are arranged on the substrate at a density of 0.5 N to 1.5 N when applied to the three-dimensional cultured skin.

[0016] A method for increasing the amount of ceramide and the mRNA expression level of a gene associated with enhancement of skin barrier function in three-dimensional cultured skin according to one embodiment of the present invention comprises applying to the three-dimensional cultured skin a microneedle device comprising a substrate and microneedles disposed on the substrate, the microneedles having a length of 300 μm to 900 μm and an average density of 28 microneedles per cm. 2 ~640 pieces / cm 2 and the load when the microneedle device is applied to the three-dimensional cultured skin is 0.5 N to 1.5 N.

[0017] The microneedle device comprises a substrate and a plurality of microneedles disposed on a major surface of the substrate.

[0018] The substrate is a base for supporting the microneedles. The shape of the substrate is not particularly limited, and can be any shape, such as a rectangle (square, rectangle, etc.), a roughly circular shape (circle, ellipse, etc.), a crescent shape, a magatama shape, or other polygonal shape, and the main surface can be flat or curved. The area of ​​the substrate is, for example, 0.5 cm 2 ~10cm 2 , 0.5cm 2 ~5cm 2 , 1cm 2 ~5cm 2 , 0.5cm 2 ~3cm 2 , or 1 cm 2 ~3cm 2 The thickness of the substrate can be, for example, 50 μm to 2000 μm, 300 μm to 1200 μm, or 500 μm to 1000 μm.

[0019] The microneedle is a minute structure rising from the main surface of the substrate, and has a tapered shape that narrows from the bottom connected to the substrate toward the tip. The shape of the microneedle can be, for example, a polygonal pyramid such as a quadrangular pyramid or a cone. The microneedle is a minute structure, and the length (height) of the microneedle in the vertical direction to the main surface of the substrate is 300 μm to 900 μm, and can be 400 μm to 600 μm or 450 μm to 550 μm. Note that microneedles of a plurality of lengths may be mixed. When the length of the microneedle is within these ranges, when the microneedle device is applied to the skin with a load of 0.5 N to 1.5 N, the microneedle does not completely penetrate the stratum corneum, and the expression amount of mRNA of a gene involved in enhancing the skin barrier function and the amount of ceramide can be increased.

[0020] The microneedles are arranged on the main surface of the substrate in, for example, a square lattice pattern, a rectangular lattice pattern, a diagonal lattice pattern, a 45° staggered pattern, or a 60° staggered pattern.

[0021] The tip of the microneedle may be a convex structure including a needle shape, but may also be flat or rounded. When the tip is flat, the area of ​​the flat part is 20 μm 2 ~1000μm 2 may be 100 μm 2 ~800μm 2 When the tip is rounded, the radius of curvature of the tip may be 2 μm to 200 μm, 5 μm to 100 μm, or 10 μm to 50 μm.

[0022] The density at which the microneedles are arranged on the substrate (needle density) is expressed by the number of microneedles per unit area in the region substantially comprising the microneedles. The region substantially comprising the microneedles is the region obtained by connecting the outermost microneedles among the multiple microneedles arranged on the microneedle device. The needle density is 28 needles / cm 2 ~640 pieces / cm 2 and 50 strands / cm2 ~200 pieces / cm 2 Or 75 strands / cm 2 ~175 pieces / cm 2 When the microneedle density is within these ranges, when the microneedle device is applied to the skin with a load of 0.5 N to 1.5 N, the microneedles do not completely penetrate the stratum corneum, and it is possible to increase the amount of ceramide and the expression level of mRNA of genes involved in enhancing the skin barrier function.

[0023] The material of the substrate and the microneedle can be, for example, silicon, silicon dioxide, ceramic, metal, polysaccharide, or synthetic or natural resin material. Examples of polysaccharide include pullulan, chitin, hyaluronic acid, sodium hyaluronate, sodium chondroitin sulfate, and chitosan. The resin material can be, for example, a biodegradable polymer such as polylactic acid, polyglycolide, polylactic acid-co-polyglycolide, polycaprolactone, polyurethane, polyamino acid (e.g., poly-γ-aminobutyric acid), or a non-degradable polymer such as polycarbonate, polyethylene, polypropylene, polyamide, polyethylene terephthalate, polymethacrylic acid, ethylene vinyl acetate, polytetrafluoroethylene, polyoxymethylene, cyclic olefin copolymer, acrylonitrile-butadiene-styrene copolymer, etc. From the viewpoint of sustained adhesion to the skin, the material is preferably a biodegradable polymer such as polylactic acid or a non-degradable polymer such as polypropylene, and particularly preferably polylactic acid, polyethylene, polypropylene, polyethylene terephthalate, or an acrylonitrile-butadiene-styrene copolymer.

[0024] Methods for manufacturing a microneedle device include wet etching or dry etching using a silicon substrate, precision machining using metal or resin (electric discharge machining, laser machining, dicing, hot embossing, injection molding, etc.), mechanical cutting, etc. By these processing methods, the microneedle and the substrate are molded integrally.

[0025] The microneedle device is applied to the three-dimensional cultured skin so that the load is 0.5N to 1.5N. The load may be 0.75N to 1.25N or 0.9N to 1.1N. By applying the microneedle device with such a load, the microneedle does not completely penetrate the stratum corneum, and the expression level of mRNA of the gene involved in enhancing the skin barrier function and the amount of ceramide can be increased. For example, the load applied to the microneedle device can be adjusted to within the above numerical range by fixing one end of a spring to the back surface (the surface without the microneedles) of the microneedle device and fixing the other end of the spring to the lid of the culture container of the three-dimensional cultured skin. Other methods for adjusting the load applied to the microneedle device include, for example, a method of placing a weight on the microneedle device and a method of pressing the microneedle device with a predetermined load using a force gauge.

[0026] Three-dimensional cultured skin is an artificial skin model similar in structure to human skin. The three-dimensional cultured skin preferably has an epidermis including all layers of the stratum corneum, stratum granulosum, stratum spinosum and stratum basale. The three-dimensional cultured skin can be purchased commercially. Examples of commercially available three-dimensional cultured skin include T-skin (EPISKIN), EPI-MODEL (Japan Tissue Engineering Co., Ltd.) and EFT-400 (MatTek). The culture conditions of the three-dimensional cultured skin are not particularly limited, and it can be cultured under general conditions, for example, in a CO2 incubator (37°C, 5% CO2). When applying the microneedle device, the three-dimensional cultured skin is cultured under the same conditions. The application time of the microneedle device can be 4 hours to 24 hours, and may be 4 hours to 12 hours, 6 hours to 10 hours, or 7 hours to 9 hours. By applying the microneedle device for such a time, the expression level of mRNA of genes involved in the enhancement of skin barrier function and the amount of ceramide can be increased.

[0027] The three-dimensional cultured skin can be used in place of human skin to test the safety and effectiveness of cosmetics and medicines. Therefore, by applying the microneedle device according to the present embodiment to the three-dimensional cultured skin, it becomes possible to evaluate the safety and effectiveness of cosmetics and medicines.

[0028] Examples of genes related to the enhancement of skin barrier function include serine palmitoyltransferase (SPTLC3), filaggrin (FLG), transglutaminase (TGM1), collagen, collagen receptor, integrin, hyaluronic acid synthase, involucrin, loricrin, laminin, and the like. The microneedle device according to the present embodiment can increase the mRNA expression level of a gene related to the enhancement of skin barrier function in three-dimensionally cultured skin cells, preferably the mRNA expression level of one or more genes selected from the group consisting of SPTLC3, FLG, and TGM1. Increasing the mRNA expression level means that the mRNA expression level is higher in three-dimensionally cultured skin cells to which the microneedle device is applied, compared to three-dimensionally cultured skin cells to which the microneedle device is not applied. The mRNA expression level can be quantified by RT-PCR. The mRNA expression level can be quantified as the expression level relative to a housekeeping gene, and examples of the housekeeping gene include β-actin, GAPDH, and 18S ribosomal RNA.

[0029] Ceramide is a general term for a group of compounds in which sphingosine and fatty acid are bonded by amide bonds. Increasing the amount of ceramide means that the amount of ceramide is greater in three-dimensionally cultured skin cells to which a microneedle device is applied, compared to three-dimensionally cultured skin cells to which a microneedle device is not applied. Here, the ceramide may be any type of ceramide, and may be one or more ceramides selected from the group consisting of ceramide 1, ceramide 2, ceramide 3, and ceramide 5, or the total amount thereof, or may be one or more ceramides selected from the group consisting of ceramide 1, ceramide 2, and ceramide 3, or the total amount thereof. EXAMPLES

[0030] (1) Fabrication of microneedle device 0.5 cm of a cylindrical substrate with a diameter of 8 mm and a thickness of 700 μm 2 In the area of ​​152 fibers / cm 2 Each microneedle has a length of 500 μm and a tip area of ​​100 μm. 2 We fabricated a polylactic acid microneedle device with a square pyramid shape.

[0031] (2) Measurement of transepidermal water loss (TEWL) A three-dimensional cultured full-thickness skin model, T-skin (6 well), was purchased from EPISKIN. Within 3 days of delivery of the T-skin, culture (37°C, 5% CO2) was started in the attached liquid medium in a 6-well plate. 24 hours after the start of culture, the medium was replaced. A microneedle device was placed on the surface of the T-skin, and the microneedle device was applied to the T-skin by applying a load of 1N, 2N, or 3N with a spring attached to the lid of the 6-well plate. The control group was cultured in a natural state without the microneedle device or spring. Each group (n=3) was cultured for 24 hours (37°C, 5% CO2). 24 hours after application of the microneedle device, the culture plate was removed from the incubator and left to stand in a clean bench for 30 minutes. The microneedle device was then removed from the T-skin, and immediately thereafter, the TEWL of the T-skin was measured with a water evaporation meter VapoMeter (Delfin Technologies). The measurement was repeated three times.

[0032] (3) Measurement of mRNA expression level Within 3 days after delivery of the T-skin, culture (37°C, 5% CO2) was started in the attached liquid medium in a 6-well plate. 24 hours after the start of culture, the microneedle device was applied in the same manner as in (2) above, except that the microneedle device was applied for 8 hours while applying a load of 1N or 2N with a spring attached to the lid of the 6-well plate. Each group was tested three times with n=3 or n=4. After 8 hours of application (37°C, 5% CO2), in order to collect only the T-skin directly below where the microneedle device had been applied, the T-skin was hollowed out with a biopsy punch (BP-80F, Kai Industries) with a diameter of 8 mm, and the skin sample was immersed in 1 mL of RNA preservation solution (RNAprotect Tissue Reagent; QIAGEN). The skin sample was stored at 4°C, and RNA extraction was performed within 3 days.

[0033] RNA was extracted from the skin samples according to the standard protocol of the RNA extraction kit (RNeasy Fibrous Tissue Mini Kit (50); QIAGEN). The skin samples were homogenized using a TissueRuptor (QIAGEN).

[0034] The RNA concentration in the extracted RNA samples was measured using a UV spectrometer (Simplinano; Biochrom). The RNA samples were stored at -80°C. The RNA samples were thawed on ice and diluted with RNase-free water to a constant concentration. The target gene primers and endogenous control (β-actin) primers were prepared using PCR reagents (TaqMan TM RNA to CT TM The mixture was mixed with RNase-Free Water (1-Step Kit; Thermo Fisher Scientific).

[0035] The measurements were performed using an Applied Biosystems® 7500fast real-time PCR device (Thermo Fisher Scientific) under the conditions shown in Table 1 below. The measurement results were obtained as relative gene expression levels using the ΔΔCt method. Each primer was purchased from Thermo Fisher Scientific. The Assay ID of each primer is shown in Table 2.

[0036] [Table 1]

[0037] [Table 2]

[0038] (4) Measurement of ceramide content Within 3 days after delivery of the T-skin, culture (37°C, 5% CO2) was started in the attached liquid medium in a 6-well plate. 24 hours after the start of culture, the microneedle device was applied in the same manner as in (2) above, except that the microneedle device was applied for 8 hours while applying a load of 1N with a spring attached to the lid of the 6-well plate. Each group was tested with n=4. After 8 hours of application (37°C, 5% CO2), the microneedle device was removed and culture of the T-skin continued. 64 hours after removing the microneedle device from the skin, the T-skin was hollowed out with a biopsy punch with a diameter of 8 mm in order to collect only the T-skin directly below where the microneedle device had been applied, and the epidermis and dermis were separated and frozen for storage.

[0039] The frozen epidermis of T-skin was placed in 150 μL of methanol solvent and homogenized using a Tissue Ruptor. After adding 300 μL of chloroform solvent, the mixture was sonicated for 10 minutes and filtered (SLLG033NB; Merck Millipore). The ceramide extraction solvent was volatilized with nitrogen gas and redissolved in 0.1 mL of chloroform:methanol (2:1) solvent to prepare the measurement sample.

[0040] 5 μL or 20 μL of the prepared sample was spotted on an HPTLC plate (Silica gel 60; Merck KGaA) using a capillary pipette (Ringcaps 10 μL; Hirschmann). 5 μL of calibration curve samples (860823P, 860924P, 860724P, 860850P and 860524P; Avanti Polar Lipids) were also spotted in the same manner. The plate was developed twice with a developing solvent of chloroform:methanol:acetic acid (190:9:1). The HPTLC plate that had been air-dried after development was immersed in a 10% copper sulfate / 8% phosphoric acid solution and heated at 180° C. for 10 minutes on a hot plate (HHP-170D; As One). The HPTLC was photographed with a camera (iPhone (registered trademark) 14; Apple) and quantitatively analyzed with ImageJ (National Institutes of Health). Quantitative values ​​were calculated based on a calibration curve on the same plate.

[0041] (5) Measurement of free amino acid content Within 3 days after delivery of the T-skin, culture (37°C, 5% CO2) was started in the attached liquid medium in a 6-well plate. 24 hours after the start of culture, the microneedle device was applied in the same manner as in (2) above, except that the microneedle device was applied for 8 hours while applying a load of 1N with a spring attached to the lid of the 6-well plate. Each group was tested with n=3. After 8 hours of application (37°C, 5% CO2), the microneedle device was removed and culture of the T-skin continued. 64 hours after removing the microneedle device from the skin, the T-skin was hollowed out with a biopsy punch with a diameter of 8 mm in order to collect only the T-skin directly below where the microneedle device had been applied, and the epidermis and dermis were separated and frozen for storage.

[0042] The frozen epidermis of T-skin was transferred to a 10 mL screw-top test tube, and 2 mL of methanol: ultrapure water (8:2) was added. 0.01 mL of internal standard solution (50 μmol / mL norvaline solution) was added. The skin fibers were homogenized to some extent using a Polytron homogenizer (10,000-18,000 rpm, 30 seconds 5-6 times). Insoluble matter was removed by centrifugation, and the extract was obtained by filtration through a microfiltration filter with a pore size of 0.2 μm. 80 μL of the extract was added to a microtube and dried in a centrifugal concentrator. 80 μL of borate buffer solution included with the amino acid derivatization reagent (AccQ-Tag Ultra; Waters) was added, and the amino acids were dissolved by stirring and ultrasonic treatment. 20 μL of amino acid derivatization reagent was added, and the mixture was immediately stirred and heated at 55 °C for 10 minutes. After cooling, the tube was spun down and transferred to an HPLC vial. The HPLC measurement was carried out under the following conditions.

[0043] Instrument: Waters UPLC H class Column: Waters AccQ·Tag Ultra 1.7μm, length 150mm x inner diameter 2mm Mobile phase: A) AccQ·Tag Ultra Eluent A B) Water / AccQ·Tag Ultra Eluent B (90 / 10) C) water D) AccQ·Tag Ultra Eluent B *Gradient elution of A, B, C, and D. Flow rate: 0.44 mL / min Column temperature: 49℃ Detector: UV (260 nm) Quantitative calculation: internal standard addition method

[0044] (6) Results of TEWL and mRNA expression of inflammatory cytokines The TEWL results are shown in Table 3. The mRNA expression levels of the inflammatory cytokines IL-6 and TNFα (values ​​normalized to the control group) are shown in Table 4.

[0045] [Table 3]

[0046] [Table 4]

[0047] As is clear from the results shown in Table 3, when the microneedle device was applied with a load of 2N or 3N, an increase in TEWL was observed. The increase in TEWL suggests damage to the stratum corneum caused by the microneedle device. On the other hand, when the microneedle device was applied with a load of 1N, no increase in TEWL was observed. As is clear from the results shown in Table 4, when the microneedle device was applied with a load of 2N, an increase in the mRNA expression level of inflammatory cytokines was observed. The increase in the mRNA expression level of inflammatory cytokines suggests damage to the stratum corneum caused by the microneedle device. On the other hand, when the microneedle device was applied with a load of 1N, no increase in the mRNA expression level of inflammatory cytokines was observed.

[0048] From the above results, it was confirmed that when the microneedle device is applied to the skin with a load of 1 N, the microneedle device does not penetrate the stratum corneum of the skin and therefore poses no safety issues.

[0049] (7) Results of mRNA expression levels of genes related to enhanced skin barrier function Table 5 shows the mRNA expression levels (normalized to the control group) of serine palmitoyltransferase (SPTLC3), filaggrin (FLG), and transglutaminase (TGM1), which are genes associated with enhanced skin barrier function.

[0050] [Table 5]

[0051] As is clear from the results shown in Table 5, when the microneedle device was applied with a load of 1 N, an increase in the mRNA expression level of genes related to enhancement of skin barrier function was observed.

[0052] (8) Ceramide content The results of the ceramide content are shown in Table 6. Total ceramide is the sum of ceramide 1, ceramide 2, ceramide 3 and ceramide 5.

[0053] [Table 6]

[0054] As is clear from the results shown in Table 6, when the microneedle device was applied with a load of 1 N, an increase in the amounts of ceramide 1, ceramide 2, ceramide 3 and total ceramide was observed.

[0055] (9) Amino acid content and mRNA expression levels of enzymes involved in filaggrin degradation The amino acid content (values ​​normalized to the control group) is shown in Table 7. The mRNA expression levels of caspase 14 (CASP14) and bleomycin hydrolase (BLMH), which are enzymes involved in filaggrin degradation (values ​​normalized to the control group), are shown in Table 8.

[0056] [Table 7]

[0057] [Table 8]

[0058] As is clear from the results shown in Table 7, when the microneedle device is applied with a load of 1N, the contents of histidine, phenylalanine and tryptophan are increased. As is clear from the results shown in Table 8, when the microneedle device is applied with a load of 1N, the mRNA expression level of the gene of the enzyme involved in the decomposition of filaggrin is increased. Filaggrin is a histidine-rich protein, and when the microneedle device is applied with a load of 1N, filaggrin is decomposed, and the amino acid content is increased, which suggests that it may act to retain moisture in the skin.

[0059] Microneedle devices were also prepared in the same manner as described in (1) above, except that the material of the microneedle device was changed from polylactic acid to polypropylene, polyethylene, polyethylene terephthalate, or acrylonitrile-butadiene-styrene copolymer. When the tests described in (2) to (9) above were carried out using these microneedle devices, the results were equivalent to those of the microneedle devices made of polylactic acid.

Claims

1. A method for increasing the mRNA expression level and ceramide level of a gene associated with enhancement of skin barrier function in three-dimensionally cultured skin, comprising: applying to the three-dimensional cultured skin a microneedle device comprising a substrate and a microneedle disposed on the substrate; The length of the microneedle is 300 μm to 900 μm; The microneedles are 28 / cm 2 ~640 pieces / cm 2 are disposed on the substrate at a density of The load when the microneedle device is applied to the three-dimensional cultured skin is 0.5 N to 1.5 N. method.

2. The method according to claim 1, wherein the gene associated with enhanced skin barrier function is one or more genes selected from the group consisting of SPTLC3, FLG and TGM1.

3. A microneedle device for increasing the amount of ceramide and the amount of mRNA expression of a gene associated with enhancement of skin barrier function in three-dimensionally cultured skin, A substrate and a microneedle disposed on the substrate, The length of the microneedle is 300 μm to 900 μm; The microneedles are 28 / cm 2 ~640 pieces / cm 2 are disposed on the substrate at a density of The load applied to the microneedle device when applied to the three-dimensional cultured skin is 0.5 N to 1.5 N. Microneedle device.

4. The microneedle device according to claim 3 , wherein the gene associated with enhanced skin barrier function is one or more genes selected from the group consisting of SPTLC3, FLG and TGM1.

Citation Information

Patent Citations

  • Compositions and methods for enhancing the flow rate of transdermal agents

    JP2001506904A

  • vaccination

    JP2004504120A

  • Percutaneous administration apparatus

    JP2007089792A

  • Percutaneous administration device

    JP2007130417A

  • Method of application of projection tool

    JP2022188715A